One of the
things which winds me up so much is how opinion changes. Convalescent plasma… is
it good or not?
High-Titer Convalescent Plasma Increases Long-Term Survival for Patients with Severe COVID-19 |
 November 16, 2022
Randomized
controlled clinical trials have evaluated the safety and efficacy of
COVID-19 convalescent plasma (CCP) and found high-titer CCP reduced the
risk of hospitalization if used early in the course of disease. However,
little is known about the long-term effect of CCP. [Read more]
|
|
Prehospital Transfusion Programs |
 Join Transfusion News Associate Editors Daniela Hermelin and Monica Pagano on Twitter Space this Friday November 18 at 11:00 ET
for a #Blooducation Baristas live event. They will delve into the
medical data & speak directly with members of the San Antonio Blood
Consortium leading the way. [Set a reminder to join us]
|
|
HbS Promotes Proinflammatory Cytokine Production in Sickle Cell Disease |
 November 9, 2022
Unlike
patients with intravascular hemolysis without sickle cell disease (SCD)
or those with β-thalassemia, patients with SCD have elevated baseline
levels of proinflammatory cytokines which increase during vaso-occlusive
crises (VOC). Monocytes are responsible for the increased production of
these cytokines, but the mechanisms behind the activation of monocytes
in patients with SCD have been elusive. [Read more]
|
No comments:
Post a Comment